Back to School: How biopharma can reboot drug development. Access exclusive analysis here
MediciNova (MNOV; Osaka:4875) withdrew a proposed follow-on offering of up to 6 million shares. MNOV,
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury